Title: Effects of Non-Cardiac/Non-neurologic Surgery and Anesthesia on the CSF Proteome,

and Modulation by the APOE Mimetic Peptide CN-105

Authors' names and affiliations: Haotian Zou, PhD[1], Michael W. Lutz, PhD[2,3], Matthew W.

Foster, PhD[4,5], Mary Cooter Wright[6], Marlene J. Violette, MS[4], Sheng Luo, PhD[1,3], Daniel

Laskowitz[2], Michael J. Devinney, MD PhD[3,6,7], Miles Berger, MD PhD[3,6,7,8*]

for the MARBLE, INTUIT & MADCO-PC Study Teams

[1]Department of Biostatistics & Bioinformatics, Duke University School of Medicine, Durham, NC,

USA

[2]Department of Neurology, Duke University School of Medicine, Durham, NC, USA

[3]Duke-UNC Alzheimers Disease Research Center, Duke University Medical Center, Durham,

NC, USA

[4]Proteomics and Metabolomics Core Facility, Duke University School of Medicine, Durham, NC,

USA

[5]Department of Medicine, Duke University School of Medicine, Durham, NC, USA

[6]Department of Anesthesiology, Duke University School of Medicine, Durham, NC, USA

[7]These authors contributed equally to this manuscript and are co-senior authors.

[8]Department of Anesthesiology, Perioperative and Pain Medicine, Stanford University School of

Medicine & Stanford Health, Stanford CA, USA.

[*]**Corresponding author:**

Miles Berger, MD

Department of Anesthesiology, Perioperative & Pain Medicine,

Stanford University School of Medicine, Stanford CA, USA

mberger1@stanford.edu

Word counts:

Abstract: 251 (not including subsection headers)

Manuscript: 3228 words total (including section headers)

Background-337, Methods 772, results 1033, discussion 1085

Running title: Human CSF Proteome changes After Surgery

Abstract

Background: Neuroinflammation is thought to contribute to postoperative central nervous

system (CNS)-related complications, and the apolipoprotein E (APOE)-mimetic peptide CN-105

blocks neuroinflammation in animal models. Thus, here we examined postoperative

cerebrospinal fluid (CSF) proteome changes and their modulation by CN-105.

Objective: To evaluate postoperative changes in the CSF proteome, and their modulation by

the APOE mimetic peptide CN-105.

Methods: We performed mass spectrometry-based proteomics on preoperative and 24-hour

postoperative CSF samples from 137 non-cardiac/non-neurologic surgery MARBLE trial

patients (age>60; ct.gov identifier: NCT03802396), who were randomized to receive APOE

mimetic peptide CN-105 (or placebo), and in an independent replication cohort. Linear

regression evaluated postoperative changes in CSF protein and pathway scores (quantified by

singe set gene set enrichment assay [ssGSEA] pathway scores), with false discovery rate

(FDR)-based multiple comparison correction.

Results: 24-hour postoperative changes were observed in 881 of 2,086 proteins (57 of which

showed a log2 fold change >0.5 or <-0.5) and in 1001 of 1854 pathways (p-FDR<0.05). Similar

magnitude temporal effects were seen in these proteins and pathways in a replication cohort.

The most significantly upregulated CSF pathways involved smooth muscle cell

migration/regulation or apoptotic signaling/regulation; the 5 most significantly downregulated

CSF pathways included NF-κB signal transduction regulation, leukocyte apoptotic process, and

sulfur and proteoglycan metabolic processes. There was no significant CN-105 effect on 24-

hour postoperative changes in CSF protein levels or ssGSEA pathway scores (p-FDR>0.05 for

all).

Conclusions: Significant postoperative changes occurred in over 40% of proteins and over 50%

of pathways in the CSF, particularly in smooth muscle, endothelial, leukocyte, and apoptosis

pathways.

Keywords: Surgery; CSF; Proteome; APOE; CN-105

BACKGROUND

Perioperative care can lead to postoperative neurocognitive complications ranging from

postoperative delirium to postoperative neurocognitive disorder and stroke.[1-3] The underlying

molecular basis for these disorders is unclear, though inflammation has been postulated to play

a key role; this can be examined using pre- and post-operative cerebrospinal fluid (CSF)

samples.[4] Indeed, CSF mass spectrometry studies have identified specific protein pathways

implicated in Alzheimer's Disease,[5-7] and a pilot mass spectrometry study identified differences

in CSF complement pathway levels over time among patients with postoperative cognitive

dysfunction.[5] Yet, few if any studies have systematically studied postoperative CSF proteome

changes among a large cohort of older non-cardiac/non-neurologic surgery patients, which

would be a first step towards understanding what postoperative central nervous system (CNS)

proteomic changes normally occur, and which might be dysregulated in patients with

perioperative neurocognitive disorders.

Additionally, there are clearly some patients who have worse long term cognitive

trajectories after surgery, such as those who carry the E4 allele of apolipoprotein E (ie *APOE4*).

APOE4 carriers (versus non-carriers) have worse long term cognitive trajectories in the 5 years

following surgery,[8] and *APOE4* carriers who underwent surgery had worse long term cognitive

decline than non-*APOE4* carriers who underwent surgery, and as compared to both *APOE4*

carriers and non-*APOE4* carriers who did not undergo surgery.[9] *APOE4* carriers have altered

CSF levels of inflammation-related proteins such as C-reactive protein (CRP), complement and

YKL-40/CH3L1,[10, 11] which may contribute to long term neurocognitive decline. Further,

modulating APOE protein signaling with the APOE mimetic penta-peptide CN-105 reduces

neuro-inflammation and improved outcomes in mice after multiple types of brain injury.[12, 13] CN-

105 was safely administered to humans in a phase I trial,[14] and to older surgical patients in a

phase II trial.[15] Thus, here we addressed two questions. First, what are the changes in the CSF

proteome from before to 24 hours after a variety of non-cardiac/non-neurologic surgeries in

older adults (ie age ≥ 60 years)? Second, does modulating APOE protein signaling with CN-105

in older patients alter these postoperative CSF protein and/or pathway changes?

METHODS

Study Overview and Intervention

We analyzed CSF samples from the triple-blind randomized phase II trial Modulating APOE to

Reduce Brain infLammation and postoperative dElirium (MARBLE), which aimed to evaluate the

safety and feasibility of the investigational product CN-105 for preventing delirium in older adults

(age ≥ 60 years) after non-cardiac/neurologic surgery (see Supplemental Digital Content

Section 1 for additional MARBLE study information). MARBLE was approved by the Western

Institutional Review Board and registered with clinicaltrials.gov prior to study initiation (ct.gov

identifier: NCT03802396). MARBLE excluded prisoners, those scheduled to receive

chemotherapy with detrimental cognitive effects within 6 weeks following surgery, those unable

to undergo a lumbar puncture (due to anticoagulation, severe anxiety, or other contraindication)

or inappropriate for inclusion based on principal investigator judgement. The primary and

secondary outcomes of the MARBLE trial have been published separately.[15]

MARBLE participants were randomized to receive either placebo, 0.1 mg/kg, 0.5 mg/kg,

or 1 mg/kg of CN-105 every 6 hours, starting just before surgery until 3 days later (for 13 doses

maximum). After enrollment, MARBLE patients underwent lumbar punctures for cerebrospinal

fluid (CSF) collection (as described[4]) before receiving the first dose of CN-105 or placebo, and

again 24 hours after the start of surgery.

Proteomics Data and Study Population

We performed mass spectrometry-based proteomics on CSF samples from all 137 MARBLE

participants who underwent preoperative and 24 hour postoperative lumbar punctures; see

Supplemental Digital Content Section 1 for details on CSF proteomic data acquisition and

processing. Protein intensities were log2 transformed for normality.

Replication Cohort

To replicate/validate our findings from the MARBLE study CSF samples in an independent

cohort, we also analyzed mass spectrometry data from CSF samples obtained before and 24

hours after surgery among 96 patients from the MADCO-PC and INTUIT studies (see

Supplemental Digital Content Section 3- Replication Cohort Description for details).[16, 17]

MADCO-PC and INTUIT were approved by the Duke IRB, and registered with clinicaltrials.gov

(NCT01993836, NCT03273335). For validation, we selected the CSF proteins or pathways that

showed a false discovery rate (FDR) significant temporal effect in the MARBLE cohort. Then we

analyzed the temporal effects of surgery on these protein or pathway levels in this replication

cohort via the same methods as in the MARBLE cohort and reported the nominal p-values.

Statistical Analysis

Missing Data Imputation and Temporal Effects on Protein Intensity and Pathway Enrichment

Scores

133 We imputed missing protein intensities via the random forest method (see Supplemental Digital

134 Content Section 1), and then examined changes in each CSF protein from the pre-operative to

135 24-hour postoperative timepoint via univariable linear regression models, with multiple

136 comparison correction using false discovery rate (FDR) across the p-values from the 2,086 CSF

137 proteins, with α=0.05[18]. To rule out the possibility of confounding by baseline patient

138 characteristics or surgery type, we also examined changes in each CSF protein and pathway

139 over this time interval using multivariable adjusted linear regression models.

140  To analyze the temporal effect of non-cardiac/neurologic surgery on protein pathway

141 enrichment scores, we performed single-sample gene set enrichment analysis (ssGSEA) to

142 provide a pathway enrichment score for each pathway in each CSF sample.[19, 20] We used the

143 Gene Ontology database for biological processes (GO-BP), version 2023.2, and extracted

144 ssGSEA scores from 1854 pathways. We computed the difference between the raw ssGSEA

145 scores at the preoperative and 24 hour postoperative timepoints for each pathway, and modeled

146 these differences via both independent univariable linear regression models and independent

147 multivariable adjusted linear regression models, with FDR adjustment across the 1,854 GO-BP

148 pathways in the analysis.

150 *APOE4 effect on Pre to Postoperative Changes in CSF Protein*

151 In a sensitivity analysis, we examine the effect of *APOE4* carrier status on pre to 24 hr

152 postoperative CSF protein changes via independent linear mixed models with CSF protein

153 levels (pre-operative and 24-hour post-operative) as the dependent variable, for each CSF

154 protein. We included the following covariates: timepoint (pre-operative or 24-hour post-

155 operative), *APOE4* carrier status, interaction between timepoint and *APOE4* carrier status, and

156 a random intercept. We tested the effects of time and *APOE4* carrier status, and their interaction

157 effect.

Unbiased Analysis of CN-105 Effect on Changes in Protein Intensity and Pathway Enrichment

Score

We assessed the effect of CN-105 on pre-operative to 24-hour post-operative changes in CSF

protein intensity levels and pathway enrichment scores using both univariable and multivariable

adjusted linear models, as described above. To assess the effect of CN-105 on pre- to 24-hour

post-operative changes in pathway enrichment scores, we first selected pathways that showed

a significant change from before to 24 hours after surgery. We fit both univariable and

multivariable adjusted linear models for pathway enrichment score temporal change, using a

regression coefficient for group (CN-105 vs placebo).

RESULTS

Baseline Characteristics, and Temporal Effects on Protein Intensity and Pathway Enrichment

Score in the MARBLE cohort

Table 1 displays the baseline MARBLE cohort characteristics; see Supplemental Digital Content

Figure S1 for CONSORT diagram, and Supplemental Digital Content Section 1 for the missing

data imputation approach and performance. Of 2,086 proteins with a missingness of ≤ 80% at

both time points in our MARBLE study mass spectrometry dataset, after FDR adjustment, 881

proteins (42.2%) showed a significant intensity level change from before to 24 hours after non-

cardiac/neurologic surgery (Fig 1A for the volcano plot), of which 57 (6.4%) proteins showed a

log_2 fold change above 0.5 or below -0.5 (i.e., these 57 proteins showed a moderate to large

effect size in the log_2 fold change).[21] Table 2 displays the most significantly up-regulated

proteins and down-regulated proteins with log_2 FC above 0.5 or below -0.5, from univariable

linear models that assessed protein level changes from before to 24 hours after surgery. The 5

most significantly changed protein levels (by t values) after surgery were FSTL3 (Follistatin Like

3; upregulated), SDF1 (Stromal Cell-Derived Factor 1; downregulated), IBP3 (Insulin-like growth

factor-binding protein 3; upregulated), SRGN (Serglycin; upregulated), and SAA1 (Serum

amyloid A-1 protein; upregulated). All of these top 5 postoperative protein level changes

remained highly significant (with the same directionality) in an FDR-corrected multivariable

analysis adjusted for numerous baseline patient characteristics (Supplemental Digital Content

Table S7, Supplemental Digital Content Data Sheet 6), which rules out the possibility that these

postoperative protein level changes were confounded by or dependent on specific patient

characteristics. The magnitude of these postoperative CSF protein level changes were also

similar across patients who underwent different types of surgery (Supplemental Digital Content

Table S1).

1001 of 1854 pathways (54.0%) showed a significant change (i.e. p-FDR<0.05) in

enrichment scores from before to 24 hours after surgery in the MARBLE dataset (Fig 1B; Table

3). Supplemental Digital Content Tables S2a and S2b list the genes for each pathway that was

up- or down-regulated after surgery, respectively. The 5 most significantly upregulated

pathways were negative regulation of smooth muscle cell migration, negative regulation of

endothelial cell apoptotic process, extrinsic apoptotic signaling pathway via death domain

receptors, regulation of extrinsic apoptotic signaling pathway via death domain receptors, and

smooth muscle cell migration. The 5 most significantly downregulated pathways were regulation

of non-canonical NF κB signal transduction, negative regulation of leukocyte apoptotic process,

sulfur compound metabolic process, proteoglycan metabolic process, and leukocyte apoptotic

process. All of these top postoperative pathway enrichment score changes (i.e., 10 out of 10

up-regulated pathways, and 10 out of 10 down-regulated pathways) remained highly significant

(and in the same direction) in an FDR-corrected multivariable analysis that was adjusted for

numerous baseline patient characteristics (Supplemental Digital Content Table S8,

Supplemental Digital Content Data Sheet 7), which rules out the possibility that these

postoperative pathway enrichment score changes were confounded by or dependent on specific

patient characteristics.

Unbiased Analysis of APOE4 carrier status and CN-105's effects on Changes in Protein

Intensity and Pathway Enrichment Score

After FDR adjustment there was no significant effect of *APOE4* carrier status, and no significant

interaction effect of *APOE4* carrier status by time, on CSF protein levels (see Supplemental

Digital Content Section 2 - *ApoE-e4* effect). Thus, *APOE4* carriers (as compared to non-carriers)

did not have significant differences in baseline or 24 hour postoperative changes in CSF protein

levels.

Next, we examined the effect of treatment with the APOE mimetic peptide CN-105 on

postoperative CSF protein and pathway changes (see Supplemental Digital Content Table S3

for baseline characteristics of MARBLE participants who received CN-105 vs placebo). There

was no significant effect of CN-105 on pre-operative to 24-hour post-operative CSF protein

intensity level changes in univariable models (Supplemental Digital Content Fig S2, Table S4) or

in multivariable models adjusted for numerous baseline patient characteristics and surgery type

(Supplemental Digital Content Table S9, Supplemental Digital Content Data Sheet 8). In

univariable models, the TM130 protein showed the largest magnitude upregulation by CN-105

($\log_2$ FC = 0.74, SE = 0.48, 95% CI = [-0.20, 1.69], Supplemental Digital Content Data Sheet 10);

and the SAA1 protein showed the largest magnitude down-regulation by CN-105 ($\log_2$ FC = -

0.78, SE = 0.27, 95% CI = [-1.30, -0.25]), though neither of these changes were significant after

FDR correction. Further, there was no significant effect of CN-105 dose level (0, 0.1, 0.5 or 1

mg/kg) on postoperative protein intensity level changes in univariable models (see

Supplemental Digital Content Table S5). There was also no significant effect of CN-105 on

postoperative CSF protein pathway enrichment score changes in univariable models (see

Supplemental Digital Content Fig. S3; Table S6) or in multivariable models adjusted for

numerous baseline patient characteristics and surgery type (Supplemental Digital Content Table

S10, Supplemental Digital Content Data Sheet 9).

Results from the Replication Cohort

To corroborate these findings, we examined pre to 24-hour postoperative changes in CSF

protein levels in an independent replication cohort of 96 participants from two other studies (see

methods for replication cohort description; Supplemental Digital Content Section 3 for additional

replication cohort information). Replication cohort baseline characteristics are provided in

Supplemental Digital Content Table S11. Of the 418 proteins that were significantly upregulated

after surgery in the MARBLE cohort (after FDR correction) and detectable in the replication

cohort, ~78% (327) were also significantly upregulated postoperatively (p-value<0.05) in the

replication cohort. Further, of the 402 proteins that were significantly downregulated after

surgery in the MARBLE cohort (after FDR correction) and detectable in the replication cohort,

~64% (259) were also significantly downregulated postoperatively (p-value<0.05) in the

independent replication cohort.

For the pathway effects, ~58% (261 of the 447 pathways that were FDR-significantly

upregulated in the MARBLE cohort) were also significantly upregulated in the replication cohort;

and ~62% (302 of the 485 pathways that were FDR-significantly down-regulated in the

MARBLE cohort) were also significantly downregulated in the replication cohort. Further, there

was a high degree of correlation between the effect sizes for, and directionality of, the

postoperative changes in both the proteins and the pathways seen in the MARBLE cohort and

the replication cohort (Figure 2A, Spearman's rho =0.861 (95% CI: [0.823, 0.892], p<0.001;

Figure 2B, Spearman's rho =0.720 (95% CI: [0.680, 0.757], p-value<0.001, respectively).

DISCUSSION

This work demonstrates widespread and significant CSF proteome changes 24 hr after non-cardiac/non-neurologic surgery in a moderate sized cohort of older adults. Further, these postoperative CSF protein and pathway changes remained highly consistent across both univariable and multivariable adjusted analyses (to rule out confounding by patient characteristics or surgery type), and in CSF samples from an independent replication cohort. We identified postoperative changes in numerous CSF proteins and pathways involved in neuroinflammation and immune system activation, particularly in monocyte and neutrophil stress response pathways. We also observed postoperative changes in endothelial, actin and collagen pathways that could allow leukocytes to enter the CNS, and changes consistent with increased postoperative apoptosis of leukocytes, endothelial cells and/or other cell types within the CNS.

Surgical trauma is thought to lead to neuroinflammation via blood brain barrier dysfunction, microglial activation, and neuronal damage.[22] Our results demonstrate substantial changes in CSF proteins within these pathways and processes at 24 hours after surgery. One of the most upregulated CSF proteins after surgery was serum amyloid A1 (SAA1), an acute phase response protein expressed in response to inflammation and tissue injury,[23] such as following surgical stress. SAA1 can cross the blood-brain barrier and cause an increase in the number of microglia and pro-inflammatory factors in the brain,[24, 25] and SAA1 protein levels also significantly increased in the hippocampus after surgery in mice.[25] CSF plasminogen activator inhibitor-1 (PAI-1) levels were also significantly up-regulated following surgery here, consistent with the established role of glucocorticoid stress hormones in shifting the hippocampal balance between expression of Pal-1 and its target, tissue plasminogen activator (tPA).[26] A cellular stress response is also consistent with the postoperative down-regulation of Collagen Type I Alpha 1 Chain (COL1A1) and Collagen Type I Alpha 2 Chain (COL1A2) observed here, since collagen expression by fibroblasts is downregulated by stress-induced adrenal cortisol release

in a dose-dependent manner[27] that can be blocked by glucocorticoid receptor (GR)

antagonists.[28] Overall, these data suggest that similar stress-induced protein level changes as

those seen in these in non-CNS biological contexts also within the human central nervous

system (ie CSF) of older adults following non-cardiac/non-neurologic surgery.

Consistent with the individual postoperative CSF collagen protein level decreases

discussed above, the collagen fibril organization pathway was also significantly downregulated

after surgery, which may facilitate the entry of peripheral leukocytes and monocytes into the

CNS, as seen in both mouse surgical models[29-31] and in older surgical patients.[32] These mouse

studies and the postoperative changes in CSF biological pathways described here are

consistent with the idea that after surgical stress in older adults, leukocytes migrate from the

vascular endothelium, cross blood vessel walls and the surrounding smooth muscle via

diapedesis to reach the brain parenchyma and interstitial fluid, which is in equilibrium with the

CSF. This process involves actin structure changes within the vascular endothelium, consistent

with the postoperative changes in CSF actin filament organization pathways seen here.[33, 34]

After entering the central nervous system, these leukocytes (especially neutrophils and

monocytes) likely undergo apoptosis due to their known short half-life (6-8 hours for

neutrophils[35]), consistent with the postoperative CSF alterations of numerous apoptosis-related

pathways observed here.

Indeed, of the top 40 CSF proteomic pathways that we found were upregulated after

surgery, 8 (including 4 of the top 5) involved inflammation, immune response, and/or

leukocyte/monocyte/neutrophil biology, 4 involved apoptosis, 7 involved wound

healing/platelets/coagulation, and 6 involved actin/cytoskeleton biology. Six pathways

downregulated after surgery were related to neuronal/synaptic function and development, and

19 were related to general growth/development (including the TGFβ pathway). Taken together,

these data fit with a model in which the postoperative activation of inflammatory and stress

pathways leads to decreased tissue development/growth processes (perhaps as a
consequence of decreased TGF beta signaling) and decreased synaptic and neuronal function.

This study has several limitations. First, while we detected over 2,000 different CSF
proteins, this also increased the burden of false discovery rate-based multiple testing correction,
which may have reduced power to detect effects of either CN-105 or *APOE4* on CSF protein or
pathway levels. Second, our moderate sample size (137 patients) relative to the number of
proteins measured (>2,000) may also explain why we did not detect statistically significant
effects (after FDR correction) of CN-105 treatment or *APOE4* carrier status. Thus, the lack of a
detectable statistically significant effect of APOE4 on CSF protein levels, or of CN-105 on
postoperative protein or pathway changes, should not be viewed as definitive evidence that
neither of these effects exists. Third, like all unbiased mass spectrometry-based proteomic
studies, the protein intensities studied here are semi-quantitative, not truly quantitative,
measurements. Fourth, here we studied CSF proteomic changes at just one postoperative time
point (i.e. 24 hours after surgery). A more detailed time course of postoperative CSF protein and
pathway changes would provide greater insights into temporal change trajectories, though this
would be challenging: it would require multiple postoperative lumbar punctures or intrathecal
catheter placements.

This study also has several key strengths. These include: 1) a moderately large cohort of
older surgical patients that underwent pre- and 24 hr post-operative lumbar punctures for
research, 2) an independent replication cohort of CSF samples from older non-cardiac/non-
intracranial surgery patients in other studies that also underwent pre- and 24 hr post-operative
lumbar punctures; 3) comprehensive unbiased proteomic analysis and rigorous statistical
analyses with FDR-based multiple comparison correction; and 4) pathway analysis using
ssGSEA and multivariable models to control for potential confounders and covariates. Finally, a
fifth strength of this work is that even though there were significant technical differences in the
mass spectroscopy assays used for the MARBLE cohort samples versus the independent

replication cohort samples, we nonetheless observed very similar postoperative changes in CSF

protein and pathway levels in both cohorts, providing strong confidence in the overall validity of

these results.

This work provides valuable insights into the CSF proteomic and pathway changes that

occur in response to surgery in older adults, and represents one of the first systematic and

unbiased descriptions of the postoperative molecular changes that take place within the central

nervous system of older adults who underwent non-cardiac/non-neurologic surgery. Further, the

postoperative protein pathway changes seen here are consistent with prior animal model work

and suggest that there is a postoperative leukocyte influx across the neurovascular endothelium

into the brain parenchyma, the brain's interstitial fluid and the CSF. Future studies should

evaluate the role of these CSF protein and pathway changes in perioperative neurocognitive

disorders among older adults, and test whether blocking specific postoperative protein or

pathway changes within the human central nervous system helps prevent these disorders.

List of abbreviations:

CSF - cerebrospinal fluid;

CNS - central nervous system;

APOE - apolipoprotein E;

MARBLE - Modulating APOE to Reduce Brain infLammation and postoperative dElirium;

FDR - false discovery rate;

ssGSEA - single-sample gene set enrichment analysis;

GO-BP - Gene Ontology database for biological processes.

Declarations

Ethics approval and consent to participate: Because Duke University owns intellectual property rights to CN-105, this study was reviewed by the Duke Office of Conflict Management, which determined that the study could be conducted at Duke under the auspices of an external IRB. Thus, MARBLE was approved by the Western Institutional Review Board and registered with clinicaltrials.gov prior to study initiation (ct.gov identifier: NCT03802396). MADCO-PC and INTUIT were approved by the Duke IRB (neither of these studies utilized CN-105), and registered with clinicaltrials.gov (NCT01993836, NCT03273335). All patients in each of these studies completed written informed consent prior to participation in any study activities.

Consent for publication: Not applicable.

Availability of data and materials: Raw data and sample-linking metadata from the MARBLE study, as well as protein .fasta file, Spectronaut spectral library and .SNE files, and protein group abundance table, have been uploaded to the ProteomeXchange consortium (PXD068209) via the MassIVE repository (ftp://MSV000099094@massive-ftp.ucsd.edu) and can be accessed using reviewer password MARBLECSF. Raw data from the replication cohort will be made available upon separate publication of that dataset or upon reasonable request.

Competing interests: MB reports receiving legal consulting fees related to postoperative neurocognitive function in older adults. For the remaining authors, no conflicts of interest were declared.

Funding: This work was supported by a Program to Accelerate Clinical Trials Grant from the Alzheimer's Drug Discovery Foundation (to MB), an International Anesthesia Research Society Mentored Research Award (to MB), NIH R01-AG076903 (to MB), NIH R03-AG050918 (to MB), NIH K76-AG057022 (to MB), and a new investigator award by the National Alzheimer's Coordinating Center (to MJD). MB acknowledges additional support from NIH R01-AG073598

(to MB), the Duke/UNC Alzheimer's Disease Research Center (5P30-AG072958, to Drs.

Heather E Whitson & Gwenn Garden), and the Duke Pepper Center (5P30-AG028716, to Drs.

Ken Schmader & Heather E. Whitson). MJD acknowledges additional support from NIH K23-

AG084898 (to MJD).

Authors' contributions:

Study concept and design: MWL, MWF, MCW, DL, MJD, MB

Proteomic Data Collection: MWF, MJV.

Statistical analysis: HZ, MWL, MWF, SL.

Data interpretation: HZ, MWL, MWF, SL, DL, MJD, MB.

Manuscript preparation: HZ, MWL, MWF, MCW, MJD, MB

Manuscript review and final approval: all authors

Acknowledgements: We thank Drs Beth Stevens, Nader Morshed and Matthew Johnson for

helpful comments on this manuscript, and the older surgical patients who participated in the

studies that provided the samples for this work.

Collaborators:

The MADCO-PC Study Group Also Includes: Brian E. Brigman, Jeffrey N. Browndyke, W.

Michael Bullock, Jessica Carter, Joseph Chapman, Brian Colin, Mary Cooter Wright, Thomas A.

D'Amico, James K. DeOrio, Ramon M. Esclamado, Michael N. Ferrandino, Jeffrey Gadsden,

Grant E. Garrigues, Stuart Grant, Jason Guercio, Dhanesh Gupta, Ashraf Habib, David H.

Harpole, Mathew G. Hartwig, Ehimemen Iboaya, Brant A. Inman, Anver Khan, Sandhya Lagoo-

Deenadayalan, Paula S. Lee, Walter T. Lee, John Lemm, Howard Levinson, Christopher

Mantyh, Joseph P. Mathew, David L. McDonagh, John Migaly, Suhail K. Mithani, Eugene

Moretti, Judd W. Moul, Mark F. Newman, Brian Ohlendorf, Alexander Perez, Andrew C.

Peterson, Glenn M. Preminger, Quintin Quinones, Cary N. Robertson, Sanziana A. Roman,

Scott Runyon, Aaron Sandler, Faris M. Sbahi, Randall P. Scheri, S. Kendall Smith, Leonard

Talbot, Julie K. M. Thacker, Jake Thomas, Betty C. Tong, Steven N. Vaslef, Nathan Waldron,

Xueyuan Wang, and Christopher Young.

The INTUIT Study Group Also Includes: Leah Acker, Cindy Louise Amundsen, Oke Anakwenze,

Harel Anolick, David Attarian, Pallavi Avasarala, Chakib Ayoub, Matthew Barber, Rachel Beach,

Andrew Berchuck, Dan G. Blazer III, Michael Bolognesi, Rachele Brassard, Brian Brigman,

William Michael Bullock, Thomas Bunning, Victor Cai, Yee Ching Vanessa Cheong, Soren K

Christensen, Brian Colin, Mary Cooter Wright, Mitchell Wayne Cox, Thomas D'Amico, Brittany

Anne Davidson, James Keith Deorio, Mark E. Easley, Sarada Eleswarpu, Detlev Erdmann,

Mariana Feingold, Michael Nicolo Ferrandino, Jeffrey Gadsden, Mark Gage, Arun Ganesh,

Grant Edward Garrigues, Rachel Adams Greenup, Ashraf Habib, Ashley Hall, Rhett K. Hallows,

David Harpole Jr, Matthew Hartwig, Laura Havrilesky, Courtney Holland, Scott Thomas

Hollenbeck, Thomas Hopkins, Edward Ross Houser ll, Samuel Huang, Ehimemen Iboaya, Brant

Inman, William Jiranek, Russel Kahmke, Amie Kawasaki, Brendan Kelleher, Jay Han Kim,

Jacob Klapper, Christopher Klifto, Rebecca Klinger, Stuart Knechtle, Sandhya A. Lagoo-

Deenadayalan, Billy Lan, Walter Lee, Howard Levinson, Brian Lewis, Michael Lipkin,

Christopher Mantyh, Hector Martinez-Wilson, John Migaly, Eugene Moretti, Judd Moul, Michael

Muehlbauer, David Murdoch, Thomas L. Novick, Kathryn Odom, Brian Ohlendorf, Steven Olson,

Deborah Oyeyemi, Shannon Page, Theodore Pappas, John Park, Andrew Peterson, Andreea

Podgoreanu, Thomas J Polascik, Dana Portenier, Glenn M. Preminger, Rebecca Ann Previs,

Edward Nandlal Rampersaud Jr, Melody Reese, Kenneth Roberts, Cary N. Robertson,

Sanziana Alina Roman, Jason Rothman, Aaron Sandler, Siddharth Sata, Charles Scales Jr,

Randall Scheri, Thorsten Seyler, Keri Anne Seymour, Nazema Y. Siddiqui, Shayan Smani,

Michael Stang, Samuel David Stanley, Katherine Sweeney, Ayesha Syed, Martin V. Taormina,

Julie Thacker, Jake Thomas, Betty Tong, Yanne Toulgoat-Dubois, Keith Vandusen, Nathan

Waldron, Alison Weidner, Kent Weinhold, Samuel Wellman, David Williams, Marty Woldorff,

Rosa Yang, Christopher Young, Sabino Zani, and Mimi Zhang.

The MARBLE Study Group Also Includes: Samuel B Adams, Cindy L Amundsen, Pallavi

Avasarala, Chakib M. Ayoub, Matthew D Barber, Andrew Berchuck, Daniel G Blazer III, Kaj

Blennow, Michael P. Bolognesi, Piper C. Boykin, Rachele Brassard, Brian E Brigman, Jeffrey N.

Browndyke, Thomas Bunning, Victor Cai, Soren K Christensen, Mary Cooter Wright, Mitchel W

Cox, Brittany A Davidson, James K DeOrio, Sarada Eleswarpu, Jacqueline M. Emerson, Detlev

Erdmann, Melissa M Erickson, Bonita L Funk, Jeffrey Gadsden, Mark J Gage, Jeff R Gingrich,

Rachel A Greenup, Christine Ha, Ashraf Habib, Ralph Abi Hachem, Ashley E Hall, Matthew G

Hartwig, Laura J Havrilesky, Mitchell T Heflin, ; J. Taylor Herbert, Courtney Holland, Scott T

Hollenbeck, Thomas J Hopkins, Bethany J. Hsia, Janet L. Huebner, Brant A Inman, David W

Jang, William A. Jiranek, Russel R Kahmke, Isaac Karikari, Amie Kawasaki, Jacob A Klapper,

Christopher S Klifto, Rebecca Klinger, Stuart J Knechtle, Sandhya A Lagoo-Deenadayalan,

Walter T Lee, Howard Levinson, Brian D Lewis, Zhong Li, Michael E Lidsky, Michael E Lipkin,

Christopher R Mantyh, Shelley R McDonald, John Migaly, Timothy E Miller, Suhail K Mithani,

Eugene W. Moretti, Paul J Mosca, Judd W Moul, Thomas L Novick, Steven A Olson, Theodore

N Pappas, John J Park, Andrew C Peterson, Brett T Phillips, Thomas J Polascik, Peter Potash,

Glenn M Preminger, Rebecca A Previs, Melody Reese Smith, Kenneth Roberts, Cary N

Robertson, Frank Rockhold, David Ryu, Charles D Scales Jr, Kevin N Shah, Randall P Scheri,

Nazema Y Siddiqui, Shayan Smani, Kevin W Southerland, Michael T Stang, Ayesha Syed,

Alicja Szydlowska, Julie K M Thacker, Niccolò Terrando, Noah J. Timko, Yanne Toulgoat-

DuBois, Keith W. VanDusen, Anthony G Visco, Alison C Weidner, Marty Woldorff, Mamata

Yanamadala, Sabino Zani Jr., and Henrik Zetterberg.

Supplementary Material

Supplemental Digital Content – Word.docx

Supplemental Digital Content – Excel.xlsx

Dataset S1.xlsx; Dataset S2.xlsx; Dataset S3.xlsx

REFERENCES

1. Evered L, Silbert B, Knopman DS, et al. Recommendations for the nomenclature of cognitive change associated with anaesthesia and surgery—2018. *Anesthesiology* 2018; 129(5):872-879.

2. Berger M, Terrando N, Smith SK, et al. Neurocognitive function after cardiac surgery: from phenotypes to mechanisms. *Anesthesiology* 2018; 129(4):829-851.

3. Vlisides P, Mashour GA. Perioperative stroke. *Can J Anaesth* 2016; 63(2):193.

4. Nobuhara CK, Bullock WM, Bunning T, et al. A protocol to reduce self-reported pain scores and adverse events following lumbar punctures in older adults. *J Neurol* 2020; 267:2002-2006.

5. VanDusen KW, Li Y-J, Cai V, et al. Cerebrospinal fluid proteome changes in older non-cardiac surgical patients with postoperative cognitive dysfunction. *J Alzheimers Dis* 2021; 80(3):1281-1297.

6. Higginbotham LA, Ping L, Dammer EB, et al. Proteomics identifies CSF biomarker panels reflective of pathological networks in the Alzheimer's disease brain: Biomarkers (non‐neuroimaging): Novel biomarkers. *Alzheimers Dement* 2020; 16:e042227.

7. Johnson EC, Dammer EB, Duong DM, et al. Large-scale proteomic analysis of Alzheimer's disease brain and cerebrospinal fluid reveals early changes in energy

metabolism associated with microglia and astrocyte activation. *Nat Med* 2020; 26(5):769-

780.

8.   Bartels K, Li Y-J, Li Y-W, et al. Apolipoprotein epsilon 4 genotype is associated with

less improvement in cognitive function five years after cardiac surgery: a retrospective

cohort study. *Canadian journal of anaesthesia= Journal canadien d'anesthesie* 2015;

62(6):618.

9.   Schenning KJ, Murchison CF, Mattek NC, et al. Surgery is associated with ventricular

enlargement as well as cognitive and functional decline. *Alzheimer's & Dementia* 2016;

12(5):590-597.

10.   Berger M, Cooter M, Roesler AS, et al. APOE4 Copy Number-Dependent Proteomic

Changes in the Cerebrospinal Fluid 1. *J Alzheimers Dis* 2021; 79(2):511-530.

11.   Ayton S, Janelidze S, Roberts B, et al. Acute phase markers in CSF reveal inflammatory

changes in Alzheimer's disease that intersect with pathology, APOE ε4, sex and age.

Prog Neurobiol 2021; 198:101904.

12.   Lei B, James ML, Liu J, et al. Neuroprotective pentapeptide CN-105 improves functional

and histological outcomes in a murine model of intracerebral hemorrhage. *Sci Rep* 2016;

6(1):34834.

13.   Laskowitz DT, Van Wyck DW. ApoE mimetic peptides as therapy for traumatic brain

injury. *Neurotherapeutics* 2023; 20(6):1496-1507.

14.   Guptill JT, Raja SM, Boakye☐Agyeman F, et al. Phase 1 randomized, double☐blind,

placebo☐controlled study to determine the safety, tolerability, and pharmacokinetics of a

single escalating dose and repeated doses of CN☐105 in healthy adult subjects. *The*

Journal of Clinical Pharmacology 2017; 57(6):770-776.

15.   Timko NJ, Cooter Wright M, Reese M, et al. The ApoE Mimetic Peptide CN-105 in

508   Older Surgical Patients: The MARBLE Phase 2 Randomized Clinical Trial. *JAMA*

509   *Surgery* 2025; Under Review.

510   16.   Berger M, Oyeyemi D, Olurinde MO, et al. The INTUIT study: investigating

511   neuroinflammation underlying postoperative cognitive dysfunction. *J Am Geriatr Soc*

512   2019; 67(4):794-798.

513   17.   Berger M, Browndyke JN, Cooter Wright M, et al. Postoperative changes in cognition

514   and cerebrospinal fluid neurodegenerative disease biomarkers. *Ann Clin Transl Neurol*

515   2022; 9(2):155-170.

516   18.   Benjamini Y, Yekutieli D. The control of the false discovery rate in multiple testing

517   under dependency. *Annals of statistics* 2001:1165-1188.

518   19.   Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a

519   knowledge-based approach for interpreting genome-wide expression profiles. *Proc Natl*

520   *Acad Sci* 2005; 102(43):15545-15550.

521   20.   Barbie DA, Tamayo P, Boehm JS, et al. Systematic RNA interference reveals that

522   oncogenic KRAS-driven cancers require TBK1. *Nature* 2009; 462(7269):108-112.

523   21.   Schork K, Podwojski K, Turewicz M, et al. Important issues in planning a proteomics

524   experiment: statistical considerations of quantitative proteomic data. Quantitative

525   Methods in Proteomics: Springer; 2021:pp. 1-20.

526   22.   Alam A, Hana Z, Jin Z, et al. Surgery, neuroinflammation and cognitive impairment.

527   *EBioMedicine* 2018; 37:547-556.

528   23.   Sun L, Ye RD. Serum amyloid A1: Structure, function and gene polymorphism. *Gene*

529   2016; 583(1):48-57.

530   24.   Gao Y, Tang S, Liu J, et al. The Administration of Circulating Extracellular Vesicles

531   Modified by Anesthesia and Surgery Induces Delirium-Like Behaviors in Aged Mice.

532   *CNS Neurosci Ther* 2025; 31(6):e70483.

533   25.   Jang WY, Lee BR, Jeong J, et al. Overexpression of serum amyloid a 1 induces

534   depressive-like behavior in mice. *Brain Res* 2017; 1654(Pt A):55-65.

535   26.   Mennesson M, Revest JM. Glucocorticoid-Responsive Tissue Plasminogen Activator

536   (tPA) and Its Inhibitor Plasminogen Activator Inhibitor-1 (PAI-1): Relevance in Stress-

537   Related Psychiatric Disorders. *Int J Mol Sci* 2023; 24(5).

538   27.   Chae M, Bae IH, Lim SH, et al. AP Collagen Peptides Prevent Cortisol-Induced Decrease

539   of Collagen Type I in Human Dermal Fibroblasts. *Int J Mol Sci* 2021; 22(9).

540   28.   Mi Y, Wang W, Zhang C, et al. Autophagic Degradation of Collagen 1A1 by Cortisol in

541   Human Amnion Fibroblasts. *Endocrinology* 2017; 158(4):1005-1014.

542   29.   Yang T, Xu G, Newton P, et al. Maresin 1 attenuates neuroinflammation in a mouse

543   model of perioperative neurocognitive disorders. *Br J Anaesth* 2019; 122(3):350-360.

544   30.   Terrando N, Eriksson LI, Kyu Ryu J, et al. Resolving postoperative neuroinflammation

545   and cognitive decline. *Ann Neurol* 2011; 70(6):986-995.

546   31.   Hirsch J, Vacas S, Terrando N, et al. Perioperative cerebrospinal fluid and plasma

547   inflammatory markers after orthopedic surgery. *J Neuroinflammation* 2016; 13:1-12.

548   32.   Berger M, Murdoch DM, Staats JS, et al. Flow cytometry characterization of

549   cerebrospinal fluid monocytes in patients with postoperative cognitive dysfunction: a

550   pilot study. *Anesthesia & Analgesia* 2019; 129(5):e150-e154.

551   33.   Heemskerk N, Schimmel L, Oort C, et al. F-actin-rich contractile endothelial pores

552   prevent vascular leakage during leukocyte diapedesis through local RhoA signalling. *Nat*

553   *Commun* 2016; 7(1):10493.

554   34.   Wójciak-Stothard B, Williams L, Ridley AJ. Monocyte adhesion and spreading on human

555   endothelial cells is dependent on Rho-regulated receptor clustering. *J Cell Biol* 1999;

556   145(6):1293.

557   35.   Summers C, Rankin SM, Condliffe AM, et al. Neutrophil kinetics in health and disease.

558   *Trends Immunol* 2010; 31(8):318-24.

Figure Legends

Figure 1. A) Volcano plot for the effect of time on CSF protein levels in the MARBLE cohort.

The x-axis is the $\log_2$ fold change of the univariate differences in protein intensity levels from

before to 24 hours after surgery. The y-axis is the $-\log_{10}$ base adjusted p-value. The horizontal

dashed line indicates $-\log_{10}$ base adjusted p-value of 0.05. The vertical dashed lines indicate

$\log_2$ fold change threshold of 0.5 and -0.5 (i.e., these proteins show moderate to large effects).

The 10 up-regulated proteins and 8 down-regulated proteins sorted by p-values and $\log_2$ fold

change threshold above 0.5 or below -0.5 are labelled below. B) Volcano Plot for the univariate

effect of time on CSF protein pathways in the MARBLE cohort, using the GO database for

biological processes (GO-BP). The horizontal dashed line indicates $-\log_{10}$ base adjusted p-

value of 0.05. The pathways with top 10 p-values are labelled below.

Figure 2. Spearman's correlations (with 95% confidence interval) between postoperative

changes in proteins and pathways between the MARBLE and replication cohorts. A) Scatterplot

of the log2 FC of the 820 proteins (A) that showed a significant temporal effect in the MARBLE

cohort (418 up-regulated proteins and 402 down-regulated proteins). The diagonal dashed line

is the identity line. B) Scatterplot of enrichment score changes for 932 CSF pathways that

showed an FDR-significant change from before to 24 hours after surgery in the MARBLE cohort

(447 up-regulated pathways and 485 down-regulated pathways). The diagonal dashed line is

the identity line. In both panels, red dots indicate proteins or pathways that were up- or down-

regulated in both cohorts; green dots indicate proteins or pathways that were up- or down-

regulated in the MARBLE cohort only. ES: Enrichment Score.

Tables

Table 1. Baseline characteristics of the 137* MARBLE study participants with preoperative and 24 hr postoperative CSF samples. The numbers are presented as mean (sd) or count (percentage).

Baseline Patient Characteristic	Value
Age	68.9 (5.0)
Sex	
Male	89 (65.0%)
Female	48 (35.0%)
Education (years)	16.3 (3.4)
Race	
Caucasian/White	118 (86.1%)
Black or African American	10 (7.3%)
Asian	2 (1.5%)
American Indian or Alaska Native	3 (2.2%)
Other/Unknown	4 (2.9%)
ApoE-e2 **copy number**	
0	122 (89.1%)
1	14 (10.2%)
2	1 (0.7%)
ApoE-e4 copy number	
0	99 (72.3%)

1	35 (25.5%)
2	3 (2.2%)
BMI	29.7 (5.0)
Surgery type	
Thoracic Surgery	9 (6.6%)
General Surgery	20 (14.6%)
Gynecologic Surgery	7 (5.1%)
Orthopedics Surgery	52 (38.0%)
ENT Surgery	7 (5.1%)
Plastic Surgery	5 (3.6%)
Urologic Surgery	37 (27.0%)
ASA physical status classification	
1	1 (0.7%)
2	47 (34.3%)
3	88 (64.2%)
4	1 (0.7%)

* See Supplemental Digital Content Table S3 for the baseline characteristics of the participants in the placebo group and CN-105 group.

Table 2. The 10 up-regulated and 8 down-regulated proteins (sorted by p-value) from univariable linear models (t-tests) that assessed changes in CSF protein levels from before to 24 hours after surgery in the MARBLE patient cohort, with a log2 fold change above 0.5 or below -0.5 (i.e., these proteins show moderate to large effects). Positive fold change values (Log_2FC) indicate an increase in the given protein level from before to 24 hours after surgery, and *vice versa*.

Up-regulated proteins		Log_2 FC	Std.Err	95% CI	t	p-value	Adj.P
FSTL3	Follistatin-related protein 3	0.884	0.033	(0.819, 0.949)	26.608	9.14E-56	9.54E-53
IBP3	Insulin-like growth factor-binding protein 3	0.557	0.029	(0.500, 0.614)	19.323	8.00E-41	1.85E-38
SRGN	Serglycin	0.809	0.042	(0.727, 0.891)	19.081	2.80E-40	5.85E-38
SAA1	Serum amyloid A-1 protein	2.255	0.122	(2.016, 2.494)	18.436	8.27E-39	1.44E-36
AGRG1	Adhesion G-protein coupled receptor G1	0.773	0.042	(0.691, 0.855)	18.361	1.23E-38	1.97E-36
TSK	Tsukushin	0.968	0.060	(0.850, 1.086)	16.036	3.77E-33	4.14E-31
IBP1	Insulin-like growth factor-binding protein 1	0.990	0.067	(0.859, 1.121)	14.756	5.09E-30	3.94E-28
PAI1	Plasminogen activator inhibitor 1	1.589	0.108	(1.377, 1.801)	14.741	5.56E-30	4.15E-28
TIMP4	Metalloproteinase inhibitor 4	0.714	0.049	(0.618, 0.810)	14.705	6.83E-30	4.91E-28
WDR1	WD repeat-containing protein 1	0.743	0.056	(0.633, 0.853)	13.204	3.91E-26	2.20E-24
Down-regulated proteins		**Log_2 FC**	**Std.Err**	**95% CI**	**T**	**p-value**	**Adj.P**
SDF1	Stromal cell-derived factor 1	-0.776	0.034	(-0.843, -0.709)	-22.489	1.16E-47	4.85E-45
CCL19	C-C motif chemokine 19	-0.878	0.079	(-1.033, -0.723)	-11.104	8.63E-21	3.00E-19
ESM1	Endothelial cell-specific molecule 1	-0.645	0.075	(-0.792, -0.498)	-8.580	1.90E-14	3.61E-13
CXL10	C-X-C motif chemokine 10	-0.597	0.074	(-0.742, -0.452)	-8.019	4.38E-13	7.24E-12
MCH	Pro-MCH	-0.606	0.107	(-0.816, -0.396)	-5.680	7.83E-08	6.66E-07
ZC3H1	Zinc finger C3H1 domain-containing protein	-0.689	0.160	(-1.003, -0.375)	-4.309	3.12E-05	1.74E-04
PAP1L	Polyadenylate-binding protein 1-like	-0.601	0.151	(-0.897, -0.305)	-3.989	1.08E-04	5.24E-04

NPS3A	Protein NipSnap homolog 3A	-0.550	0.183	(-0.909, -0.191)	-2.999	3.22E-03	1.06E-02

* Abbreviations: Std.Err: standard error; Adj.P: adjusted p-value. FC: fold change. CI: confidence interval.

* See Supplemental Digital Content Table S7 for multivariable model adjusted for CN-105, age, sex, education years, *ApoE*-e2 copy number, *ApoE*-e4 copy number, BMI, surgery type, ASA physical status classification, and baseline protein intensity.

Table 3. The 10 up-regulated and 10 down-regulated pathways (sorted by p-value) from the univariable linear models that assessed the temporal effect of the pathway enrichment score from before to 24 hours after surgery, based on the Gene Ontology database for biological processes (GO-BP) in the MARBLE cohort. The top panel displays pathways that are the most highly up-regulated; the bottom panel displays pathways that are the most down-regulated. Beta coefficients are from linear models that assessed the effect of time (ie from before to 24 hrs after anesthesia and surgery) on the ssGSEA enrichment scores.

Up-regulated pathways	Beta	Std.Err	95% CI	t	p-value	Adj.P
negative regulation of smooth muscle cell migration	77.574	4.183	(69.375, 85.773)	18.547	4.60E-39	8.53E-36
negative regulation of endothelial cell apoptotic process	93.981	5.417	(83.364, 104.598)	17.349	2.76E-36	2.56E-33
extrinsic apoptotic signaling pathway via death domain receptors	67.583	4.641	(58.487, 76.679)	14.563	1.54E-29	9.49E-27
regulation of extrinsic apoptotic signaling pathway via death domain receptors	79.959	5.556	(69.069, 90.849)	14.392	4.08E-29	1.89E-26
smooth muscle cell migration	40.878	3.068	(34.865, 46.891)	13.323	1.96E-26	7.28E-24
regulation of fibrinolysis	43.100	3.474	(36.291, 49.909)	12.407	4.10E-24	1.27E-21
muscle cell migration	35.009	2.883	(29.358, 40.660)	12.144	1.92E-23	5.08E-21
endothelial cell apoptotic process	61.060	5.199	(50.870, 71.250)	11.744	2.01E-22	4.65E-20
angiogenesis involved in wound healing	67.270	5.860	(55.784, 78.756)	11.480	9.48E-22	1.95E-19
actin filament organization	36.949	3.245	(30.589, 43.309)	11.386	1.65E-21	3.05E-19
Down-regulated pathways	Beta	Std.Err	95% CI	t	p-value	Adj.P
regulation of non-canonical NF κB signal transduction	-50.390	4.940	(-60.072, -40.708)	-10.200	1.71E-18	1.98E-16
negative regulation of leukocyte apoptotic process	-63.415	6.381	(-75.922, -50.908)	-9.938	7.86E-18	7.28E-16
sulfur compound metabolic process	-25.949	2.638	(-31.119, -20.779)	-9.836	1.42E-17	1.16E-15

proteoglycan metabolic process	-36.575	3.801	(-44.025, -29.125)	-9.623	4.88E-17	3.77E-15
leukocyte apoptotic process	-46.150	4.912	(-55.778, -36.522)	-9.395	1.82E-16	1.13E-14
neuron projection extension involved in neuron projection guidance	-42.305	4.533	(-51.190, -33.420)	-9.333	2.61E-16	1.55E-14
regulation of leukocyte apoptotic process	-48.549	5.204	(-58.749, -38.349)	-9.328	2.67E-16	1.55E-14
response to chemokine	-61.512	6.609	(-74.466, -48.558)	-9.307	3.03E-16	1.66E-14
glycoprotein metabolic process	-28.814	3.155	(-34.998, -22.630)	-9.131	8.29E-16	3.94E-14
negative regulation of axon extension involved in axon guidance	-43.733	4.843	(-53.225, -34.241)	-9.030	1.48E-15	6.39E-14

* Abbreviations: Std.Err: standard error; Adj.P: adjusted p-value. CI: confidence interval.

* See Supplemental Digital Content Table S8 for multivariable model adjusted for CN-105, age, sex, education years, *ApoE*-e2 copy number, *ApoE*-e4 copy number, BMI, surgery type, ASA physical status classification, and baseline enrichment score.